Table I.
In vivo efficacy of aspirin in combination with erlotinib against A549 xenografts.
| No. of animals | Body weight (g) | ||||||
|---|---|---|---|---|---|---|---|
| Group | Start | End | Start | End | Inhibition rate (%) | Mean RTV | T/C (100%) |
| Control | 6 | 6 | 18.7±1.5 | 22.1±2.7 | – | 14.2 | – |
| Aspirin (100 mg/kg) | 6 | 6 | 18.6±1.0 | 21.5±1.1 | 0 | 13.3 | 93.7 |
| Erlotinib (20 mg/kg) | 6 | 6 | 18.7±1.0 | 21.1±0.8 | 19.2 | 9.7a | 68.3 |
| Combination | 6 | 6 | 19.2±0.5 | 22.6±0.8 | 55.8 | 3.1b–d | 21.8 |
a
Relative to control, P<0.05
b
Relative to control, P<0.01
c
Relative to the aspirin group, P<0.05
d
Relative to the erlotinib group, P<0.05. RTV, relative tumor volume; T/C, RTV of treated group/mean RTV of control group.